Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation

Recruiting now · Not applicable

Conditions studied: Liver Metastasis Colon Cancer

In brief

To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.

Key facts

Study ID

NCT04798898

Run by

University of Aarhus

People needed

200

Starts

2022-11-14

Expected to finish

2026-12-01

Last updated by the study team

2024-12-05

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with colorectal liver metastases planned for resection
• At least one tumor size >=3cm
• Performance status 0-1

You may not qualify if…

• Liver cirrhosis
• Extrahepatic metastases that can not be addressed curatively
• Other malignant diseases within 5 years prior to diagnosis
• Prior RFA treatment

Where it is running

• Aarhus University Hospital, Department of Surgery — Aarhus, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.